Swipe om te navigeren naar een ander artikel
To examine the effects of a digestive enzyme supplement in improving expressive language, behaviour and other symptoms in children with Autism Spectrum Disorder. Randomized, double-blind placebo-controlled trial using crossover design over 6 months for 43 children, aged 3–8 years. Outcome measurement tools included monthly Global Behaviour Rating Scales, Additional Rating Scales of other symptoms by parents and therapists, and monthly completion of the Rescorla Language Development Survey. Compared with placebo, treatment with enzyme was not associated with clinically significant improvement in behaviour, food variety, gastrointestinal symptoms, sleep quality, engagement with therapist, or the Language Development Survey Vocabulary or Sentence Complexity Scores. A small statistically significant improvement on enzyme therapy was seen for the food variety scores. No clinically significant effect improvement of autism symptoms with enzyme use was shown with this trial, however, possible effects on improvement in food variety warrants further detailed investigation.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Aman, M. G., & Singh, N. N. (1986). Aberrant behavior checklist: Manual. East Aurora, NY: Slosson Educational Publications.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington, DC: Author.
Autism and Developmental Disabilities Monitoring (ADDM) Network. (2007). Prevalence of the autism spectrum disorders in multiple areas of the United States, surveillance years 2000 and 2002. http://www.cdc.gov/ncbddd/dd/addmprevalence.htm. Retrieved 27 July 2007.
Brudnak, M. A., Rimland, B., Kerry, R. E., Dailey, M., Taylor, R., Stayton, B., et al. (2002). Enzyme-based therapy for autism spectrum disorders–Is it worth another look? Medical Hypotheses, 58(5), 422–428.
D’Eufemia et al. (1996). Abnormal intestinal permeability in children with autism. Acta Paediatrica, 85, 1076–1079.
Houston, D. (2009). Houston Nutraceuticals Inc. Peptizyde product information accessed 24/12/09 via https://www.houston-enzymes.com/store/product.php?p=6&c=1.
Matson, J. L., & Fodstadt, J. C. (2009). The treatment of food selectivity and other feeding problems in children with autism spectrum disorders. Research in Autism Spectrum Disorders, 3, 455–461. CrossRef
Millward, C., Ferriter, M., Calver, S., & Connell-Jones, G. (2008). Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database of Systematic Reviews, (2). Art. No.: CD003498. doi: 10.1002/14651858.CD003498.pub3.
Rescorla, L. (1989). The language development survey: A screening tool for delayed language in toddlers. Journal of Speech and Hearing Disorders, 54, 587–599. PubMed
Sparrow, S. S., Balla, D. A., & Cicchetti, D. (1984). Vineland adaptive behavior scales. Minnesota: AGS Publishing.
Wakefield, A. J., Puleston, J. M., Montgomery, S. M., Anthony, A., O’Leary, J. J., & Murch, S. H. (2002). Review article: The concept of enter-colonic encephalopathy, autism and opioid receptor ligands. Alimentary Pharmacology & Therapeutics, 16, 663–674. CrossRef
Weber, W. (2007). Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatric Clinics of North America, 54, 983–1006.
Wetherby, A., & Prizant, B. M. (1993). Communication and symbolic behavior scales. New York: Applied Symbolix.
White, J. F. (2003). Intestinal pathophysiology in autism. Experimental Biology and Medicine, 228, 639–649. PubMed
- Digestive Enzyme Supplementation for Autism Spectrum Disorders: A Double-Blind Randomized Controlled Trial
Sujeeva A. Munasinghe
John A. Wray
- Springer US